[1] [1] HOLDEN B A，FRICKE T R，WILSON D A，et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050［J］. Ophthalmology，2016，123（5）：1036-1042.

[2] [2] COOPER J，TKATCHENKO A V. A review of current concepts of the etiology and treatment of myopia［J］. Eye & Contact Lens，2018，44（4）：231-247.

[7] [7] GRZYBOWSKI A，ARMESTO A，SZWAJKOWSKA M，et al. The role of atropine eye drops in myopia control［J］. Current Pharmaceutical Design，2015，21（32）：4718-4730.

[8] [8] GREENE P R. Mechanical considerations in myopia： relative effects of accommodation，convergence，intraocular pressure，and the extraocular muscles［J］. American Journal of Optometry and Physiological Optics，1980，57（12）：902-914.

[9] [9] MCBRIEN N A，MOGHADDAM H O，REEDER A P. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism［J］. Investigative Ophthalmology & Visual Science，1993，34（1）：205-215.

[12] [12] TIGGES M，IUVONE P M，FERNANDES A，et al. Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys［J］. Optometry & Vision Science： Official Publication of the American Academy of Optometry，1999，76（6）：397-407.

[13] [13] BARATHI V A，BEUERMAN R W. Molecular mechanisms of muscarinic receptors in mouse scleral fibroblasts： prior to and after induction of experimental myopia with atropine treatment［J］. Molecular Vision，2011，17：680-692.

[14] [14] WU H，CHEN W，ZHAO F，et al. Scleral hypoxia is a target for myopia control［J］. Proceedings of the National Academy of Sciences of the United States of America，2018，115（30）： E7091-E7100.

[15] [15] ZHANG S，ZHANG G Y，ZHOU X，et al. Changes in choroidal thickness and choroidal blood perfusion in guinea pig myopia［J］.Investigative Ophthalmology & Visual Science ，2019，60（8）：3074-3083.

[16] [16] ZHOU X，ZHANG S，ZHANG G，et al. Increased choroidal blood perfusion can inhibit form deprivation myopia in guinea pigs［J］.Investigative Ophthalmology & Visual Science，2020，61（13）：25.

[17] [17] STONE R A，PARDUE M T，IUVONE P M，et al. Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms［J］.Experimental Eye Research，2013，114：35-47.

[18] [18] UPADHYAY A，BEUERMAN R W. Biological mechanisms of atropine control of myopia［J］. Eye & Contact Lens，2020，46（3）：129-135.

[19] [19] MATHIS U，FELDKAEMPER M，WANG M，et al. Studies on retinal mechanisms possibly related to myopia inhibition by atropine in the chicken［J］. Graefes Arch Clin Exp Ophthalmol，2020，258（2）：319-333.

[20] [20] CRISTALDI M，OLIVIERI M，PEZZINO S，et al. Atropine differentially modulates ecm production by ocular fibroblasts，and its ocular surface toxicity is blunted by colostrum［J］. Biomedicines，2020，8（4）：78.

[21] [21] CHUA W H，BALAKRISHNAN V，CHAN Y H，et al. Atropine for the treatment of childhood myopia［J］. Ophthalmology，2006，113(12):2285-2291.

[22] [22] CHIA A，CHUA W H，CHEUNG Y B，et al. Atropine for the treatment of childhood myopia： safety and efficacy of 0.5%，0.1%，and 0.01% doses （Atropine for the treatment of myopia 2）［J］. Ophthalmology，2011，119（2）：347-354.

[23] [23] YAM J C，JIANG Y N，TANG S M，et al. Low-Concentration Atropine for Myopia Progression （LAMP） study： a randomized，doubleblinded，placebo-controlled trial of 0.05%，0.025%，and 0.01% atropine eye drops in myopia control［J］. Ophthalmology，2019，126（1）：113-124.

[24] [24] LI F F，ZHANG Y Z，ZHANG X J，et al. Age effect on treatment responses to 0.05%，0.025%，and 0.01% atropine： low-concentration atropine for myopia progression study［J］. Ophthalmology，2021，128（8）：1180-1187.

[25] [25] YAM J C，ZHANG X J，ZHANG Y Z，et al. Three-year clinical trial of Low-concentration atropine for myopia progression （LAMP）study： continued versus washout： phase 3 report［J］. Ophthalmology，2022，129（3）：308-321.

[26] [26] HA A，KIM S J，SHIM S R，et al. Efficacy and safety of 8 atropine concentrations for myopia control in children： a network meta-analysis［J］. Ophthalmology，2022，129（3）：322-333.

[28] [28] YAM J C，ZHANG X J，ZHANG Y Z，et al. Effect of low-concentration atropine eyedrops vs placebo on myopia incidence in children：the LAMP2 randomized clinical trial［J］. JAMA，2023，329（6）：472-481.

[29] [29] WANG W Q，ZHANG F Y，YU S A，et al. Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective，randomized，double-masked，and crossover trial［J］. European Journal of Pediatrics，2023，182（6）：2597-2606.

[30] [30] REPKA M X，WEISE K K，CHANDLER D L，et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control： a randomized clinical trial［J］. JAMA Ophthalmology，2023，141（8）：756-765.

[32] [32] DU L L，CHEN J，DING L，et al. Add-on effect of 0.01% atropine in orthokeratology wearers for myopia control in children： a 2-year retrospective study［J］. Ophthalmology and Therapy，2023，12（5）：2557-2568.

[33] [33] GONG Q W，JANOWSKI M，LUO M，et al. Efficacy and adverse effects of atropine in childhood myopia： a meta-analysis［J］. JAMA Ophthalmology，2017，135（6）：624-630.

[34] [34] CHIA A，LU Q S，TAN D. Five-year clinical trial on atropine for the treatment of myopia 2： myopia control with atropine 0.01% eyedrops［J］. Ophthalmology，2016，123（2）：391-399.

[35] [35] WU T E J，YANG C C，CHEN H S. Does atropine use increase intraocular pressure in myopic children？［J］. Optometry and Vision Science，2012，89（2）： E161-E167.

[36] [36] CHENG J Y，YANG Y J，KONG X H，et al. The effect of 0.01% atropine eye drops on the ocular surface in children for the control of myopia-the primary results from a six-month prospective study［J］. Therapeutics and Clinical Risk Management，2020，16：735-740.

[37] [37] SHIH K C，CHAN T C Y，NG A L，et al. Use of atropine for prevention of childhood myopia progression in clinical practice［J］. Eye & Contact Lens，2016，42（1）：16-23.

[38] [38] TONG L，HUANG X L，KOH A L T，et al. Atropine for the treatment of childhood myopia： effect on myopia progression after cessation of atropine［J］. Ophthalmology，2009，116（3）：572-579.

[39] [39] CHIA A，CHUA W H，WEN L，et al. Atropine for the treatment of childhood myopia： changes after stopping atropine 0. 01%，0. 1% and 0. 5%［J］. American Journal of Ophthalmology，2014，157（2）：451-457.